The UK regulator, the MHRA, has approved Regeneron Pharmaceuticals, Inc./Roche Holding AG’s monoclonal antibody combination, casirivimab plus imdevimab (REGN-COV), as Ronapreve for the treatment and prevention of COVID-19.
The move follows what the MHRA called a “thorough review of the evidence” and a recommendation from the government’s independent...








